Creso Pharma Strengthens Its Presence In Switzerland With The Brewing Of OBMJ Beers At Einhorn Bräu

CPH

Creso Pharma Limited (ASX: CPH) is a pharmaceutical company based in New South Wales, Australia. It has one office in Switzerland as well and has entered into the Canadian market by acquiring 100 % shares of Mernova. Mernova, based in Nova Scotia, is a Medical Cannabis company. CPH is engaged in the manufacturing of high-quality cannabis product for animals as well as people using GMP development and manufacturing standards for its products as a reference of quality excellence. It has launched two cannabidiol products, cannaQIX and anibidiol, in Switzerland and is the first company in Australia to import medicinal cannabis. 

CPH, LGC Capital, and Baltic Beer Company Ltd. had entered into a joint venture earlier forming CLV Frontier Brands Pty Ltd. (CLV). Baltic Beer Company Ltd. is a UK-based beer company selling beers around the world under the brand name Viru Premium Estonian Beer. LGC Capital is a Canada based investment holding company listed on TSX with its investments in private cannabis operations all over the world. All the three entities hold the same proportion in the joint venture.

Today the company has announced that Einhorn Bräu has launched its licensed production of the Old Boy Mary Jane (OBMJ) beer range in Switzerland. This entry in the Swiss beer market with cannabis flavoured beers will provide CPH an opportunity to position itself as a leading top-quality cannabis company in support of its CBD nutraceutical flagship product cannaQIX. Einhorn Bräu will brew, market and sell OBMJ beers Ghost Bog Hazy IPA, Big Egg Mountain Baltic Porter, and Improper Pils enhancing the profile of the cannaQIX product brand.

Einhorn Bräu is a high-quality craft beer producer based in Switzerland. It uses only selected natural ingredients without any chemicals or additives to make beer. Einhorn Bräu had entered into a licensing agreement with CLV to produce OBMJ beers range. The company distributes its beers through online, retail, and beverage shops across Switzerland and has won the Swiss Beer Awards 2017 and 2018.

In October 2018, The Baltic Beer Star 2018 competition was held in Riga where Big Egg Mountain Baltic Porter won Silver Medal, and Ghost Bog Hazy IPA and Improper Pils won Bronze Medals.

These new beers are expected to show the synergy between genus Humulus (Hops) and cannabis (Hemp) which are biologically closely related. In the UK, it is listed with National and Regional wholesalers and online retailers such as Beers of Europe and The Drink Shop.

As per the management, the businesses are very excited to work together, and brew innovative cannabis flavoured Swiss beer.

Looking at Creso Pharma Limited’s stock performance and the return it has posted over the last few months, the stock has generated a positive return of 12.94% during the past three months. It is currently trading at $0.475 (at the close of the market on 30 January 2019) with a dip of 1.042% in the price during the day’s performance. CPH has approx. 124.19 million shares outstanding with the market cap of circa $59.61 million. The 52-week high and low for CPH are marked at $1.085 and $0.335 respectively.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.